How TWOPAGES Connects Craftsmanship and Service to Simplify Custom Window Treatments

NEW YORK and LOS ANGELES and OTTAWA, ON, Oct. 30, 2026 /PRNewswire/ -- For many homeowners, custom window treatments promise a perfect fit but deliver uncertainty. TWOPAGES is closing that gap by connecting vertically integrated manufacturing with professional support throughout the buying journey. Through its Behind the Curtain documentary series, TWOPAGES offers a closer look at the craftsmanship behind its custom window treatments.

TWOPAGES Full-Service Window Treatment Experience

Craftsmanship Behind Every Order

From fabric development, dyeing, printing and embroidery to skilled manual cutting and sewing, shaping and quality inspection, TWOPAGES manages every major production stage with care and precision. Close attention to fabric behavior, measurements, seams and finishing helps ensure consistent quality, accurate dimensions, graceful drape and lasting performance. The brand offers 50+ collections and 1,000+ fabrics, with standard drapery production taking 3–7 days*.

Beyond craftsmanship, TWOPAGES pairs its manufacturing strength with three services supporting product selection, measurement, and installation.

Through its Design Consult Service, customers receive one-on-one guidance on fabrics, colors, hardware, and products based on their space, lifestyle, and budget. Zoom Measuring Consult provides real-time guidance; the first 20 minutes are complimentary. In eligible locations, the In-Home Measurement & Installation Service offers professional measurement or installation.

By linking front-end service with back-end production, TWOPAGES reduces uncertainty throughout the custom window treatment process.

Beyond the Window Treatments

For TWOPAGES, window treatments serve a purpose beyond decoration. They shape light, privacy, and comfort at home. Through thoughtful material selection, precise craftsmanship, and comprehensive support, the brand helps homeowners achieve these benefits more easily.

"We believe light shapes a space, and a space shapes how people feel. That is why every detail matters—from the way a fabric filters natural light to the precision of its construction and the support customers receive throughout the process," said Ray Chen, Founder and CEO of TWOPAGES. "Our goal is not simply to make beautiful window treatments, but to help create homes where people can slow down, feel at ease, and be more present in everyday life."

Since 2015, TWOPAGES has served over 600,000 households worldwide, a record of trust built on craftsmanship, service, and a belief that a home should give people space to slow down, reconnect, and simply be.

To explore TWOPAGES custom window treatments and get expert help with design, measuring and installation, visit twopagescurtains.com.

*Production timelines vary for other categories, including Roman shades and bamboo shades.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

How TWOPAGES Connects Craftsmanship and Service to Simplify Custom Window Treatments

BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.

A Three-Year Partnership Built on a Trusted R&D Model

Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.

In-Depth Discussions Explore New Collaboration Opportunities

During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.

Laboratory Tour

Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"